Abstract
With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.
| Original language | English (US) |
|---|---|
| Journal | Therapeutic Advances in Chronic Disease |
| Volume | 10 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- osteoarthritis
- rheumatoid arthritis
- stromal cell-derived factor-1 (SDF1)
ASJC Scopus subject areas
- Medicine (miscellaneous)
Cite this
Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis. / Bragg, Robert; Gilbert, William; Elmansi, Ahmed M.; Isales, Carlos M.; Hamrick, Mark W.; Hill, William D.; Fulzele, Sadanand.
In: Therapeutic Advances in Chronic Disease, Vol. 10, 01.01.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Stromal cell-derived factor-1 as a potential therapeutic target for osteoarthritis and rheumatoid arthritis
AU - Bragg, Robert
AU - Gilbert, William
AU - Elmansi, Ahmed M.
AU - Isales, Carlos M.
AU - Hamrick, Mark W.
AU - Hill, William D.
AU - Fulzele, Sadanand
PY - 2019/1/1
Y1 - 2019/1/1
N2 - With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.
AB - With age, joints become subject to chronic inflammatory processes that lead to degeneration of articular cartilage. Although multifactorial, cytokines have been shown to play a role in the pathogenesis of these chronic disease states. Stromal cell-derived factor 1 (SDF-1) is a chemokine that has been shown to be active in homeostatic mechanisms and developmental processes throughout the body, such as endochondral bone formation. SDF-1 plays a role in the transition from cartilage to bone. Although it has been shown to be a factor in normal development, it has also been shown to involve in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, SDF-1 has been shown to stimulate the recruitment of proinflammatory cells, as well as osteoclasts to the synovium, aiding in the facilitation of synovial degradation. Similarly, in OA, SDF-1 has been shown to regulate key proteins involved in the degradation of the cartilage of the joint. Because of its role in degenerative joint disease, SDF-1 has been investigated as a potential therapeutic target. Animal studies have been employing SDF-1 inhibitors, such as AMD3100 and T140, to study their effects on attenuating degenerative joint disease. These studies have shown promising results in slowing the progression of cartilage degradation and could potentially be used as therapeutic target for humans OA and RA.
KW - osteoarthritis
KW - rheumatoid arthritis
KW - stromal cell-derived factor-1 (SDF1)
UR - http://www.scopus.com/inward/record.url?scp=85074132685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074132685&partnerID=8YFLogxK
U2 - 10.1177/2040622319882531
DO - 10.1177/2040622319882531
M3 - Review article
AN - SCOPUS:85074132685
VL - 10
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
ER -